2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens, Greece.
Climacteric. 2013 Apr;16(2):258-64. doi: 10.3109/13697137.2012.668251. Epub 2012 May 29.
To investigate the effect of tibolone and raloxifene on the serum apoptotic markers soluble Fas (sFas), soluble Fas ligand (sFasL) and cytochrome-c (cyt-c) in postmenopausal women.
A total of 89 healthy postmenopausal women, attending the University Menopause Clinic, were randomly allocated to tibolone (n =30), raloxifene (n =29) or no treatment (n =30). Serum apoptotic markers sFas, sFasL and cyt-c were measured at baseline and at 6 months.
Serum sFasL decreased significantly in women receiving tibolone (baseline: 53.8±28.3 pg/ml, 6 months: 40.45±19.2 pg/ml, p =0.001), whilst sFas levels did not significantly change in this group. Serum sFas or sFasL did not change either in the raloxifene group or in the control group. Serum cyt-c concentrations were under the detection limit of the assay in all women assessed.
Tibolone use resulted in a significant decrease in serum sFasL, but not in serum sFas. Raloxifene had no effect on either sFas or sFasL. These results may indicate that tibolone use is associated with a decrease in receptor-mediated apoptosis.
探讨替勃龙和雷洛昔芬对绝经后妇女血清凋亡标志物可溶性 Fas（sFas）、可溶性 Fas 配体（sFasL）和细胞色素-c（cyt-c）的影响。
共有 89 名健康的绝经后妇女，参加了大学绝经期诊所，被随机分配到替勃龙（n=30）、雷洛昔芬（n=29）或不治疗（n=30）组。在基线和 6 个月时测量血清凋亡标志物 sFas、sFasL 和 cyt-c。
接受替勃龙治疗的妇女血清 sFasL 显著下降（基线：53.8±28.3 pg/ml，6 个月：40.45±19.2 pg/ml，p=0.001），而 sFas 水平在该组没有显著变化。雷洛昔芬组或对照组的 sFas 或 sFasL 均未发生变化。所有接受评估的妇女的血清 cyt-c 浓度均低于检测限。
替勃龙的使用导致血清 sFasL 显著下降，但对血清 sFas 没有影响。雷洛昔芬对 sFas 或 sFasL 均无影响。这些结果可能表明替勃龙的使用与受体介导的凋亡减少有关。
Zotero 插件